Figure 1. Impact of VEGFA/VEGFR-targeted therapeutics on tumor-induced immunosuppression. Tumor-derived vascular endothelial growth factor A (VEGFA) can block the maturation of dendritic cells (DCs) and induce the expansion of myeloid-derived suppressor cells. Immature DCs as well as MDSCs favor the generation of regulatory T cells (Tregs). VEGFA can also induce the proliferation of VEGF receptor 2 (VEGFR2)⁺ Tregs. VEGFA/VEGFR-targeted therapies can exert antineoplastic effects by interfering with all these mechanisms.